Last edition
News about Quality / GMP
Lupin and Natco Secure USFDA Approval for Generic Cancer Drug Eribulin Mesylate Injection
Lupin and Natco Pharma have received USFDA approval for Eribulin Mesylate Injection, a generic equivalent of Halaven, used in the treatment of advanced breast cancer and liposarcoma.
Quality / GMP | 03/06/2026 | By News Bureau
Johnson & Johnson’s IL-23 inhibitor becomes the first in its class to include evidence of structural joint damage inhibition in adults with active psoriatic arthritis.
Quality / GMP | 30/05/2026 | By News Bureau | 110
Abbott has received CE Mark approval for Libre Duo, the world’s first dual glucose-ketone sensing technology, offering continuous monitoring of both glucose and ketone levels to help prevent diabetic ketoacidosis and support safer diabetes care.
Quality / GMP | 30/05/2026 | By News Bureau
Antengene Corporation receives CDE endorsement to begin pivotal phase 3 CLINCH-3 study of ATG-022
Antengene has received approval from China’s Center for Drug Evaluation to initiate the pivotal Phase 3 CLINCH-3 study of ATG-022, advancing the development of its innovative antibody-drug conjugate for CLDN18.2-positive gastric cancers.
Quality / GMP | 30/05/2026 | By News Bureau
The World Health Organisation has issued its first recommendation on doxycycline Post-Exposure Prophylaxis (doxyPEP) for preventing bacterial STI, marking a significant step towards expanding evidence-based STI prevention options for vulnerable populations.
Quality / GMP | 30/05/2026 | By News Bureau
Travere Therapeutics Receives USPTO Patent Allowance for Filspari Use in IgA Nephropathy
Travere Therapeutics has secured a Notice of Allowance from the USPTO for a patent application covering specific methods of using Filspari (sparsentan) in the treatment of IgA nephropathy, strengthening its rare kidney disease portfolio.
Quality / GMP | 29/05/2026 | By News Bureau | 138
Aphios Corporation has received a Notice of Allowance from the USPTO for a divisional patent application covering novel Bryoid compositions and manufacturing methods aimed at advancing therapies for neurodegenerative diseases, HIV latency and cancer.
Quality / GMP | 29/05/2026 | By News Bureau
FDA Grants Priority Review to Sanofi's Venglustat for Type 3 Gaucher Disease
Sanofi’s brain-penetrant investigational therapy venglustat has received FDA priority review after phase 3 data demonstrated positive efficacy and safety outcomes in patients with type 3 Gaucher disease.
Quality / GMP | 29/05/2026 | By News Bureau
GSK Reports Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B Treatment
GSK’s investigational antisense oligonucleotide bepirovirsen demonstrated statistically significant functional cure rates in chronic hepatitis B patients, offering a potential alternative to lifelong antiviral therapy.
Quality / GMP | 29/05/2026 | By News Bureau | 133
Indoco Remedies Secures EU GMP Certification for Baddi Formulation Plant III
Indoco Remedies has received EU GMP certification for its Baddi Plant III formulation facility following a successful inspection conducted in April 2026.
Quality / GMP | 28/05/2026 | By News Bureau | 131
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy